Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Schedule of collaboration revenue

Net product sales consist of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
Net Product Sales in the United States	2019		2018		2019		2018
EYLEA®	$	1,187.7	$	1,021.8	$	3,422.1	$	2,997.8
Libtayo®	47.6		—		115.2		—
ARCALYST®	3.0		3.7		10.7		12.0
	$	1,238.3	$	1,025.5	$	3,548.0	$	3,009.8

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which were previously terminated):

	Three Months Ended September 30,				Nine Months Ended September 30,
Bayer EYLEA Collaboration Revenue	2019		2018		2019		2018
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	275.0	$	243.2	$	793.3	$	721.5
Reimbursement of Regeneron EYLEA development expenses	5.0		1.7		15.6		8.8
Other	22.8		20.7		59.1		45.4
	$	302.8	$	265.6	$	868.0	$	775.7

The collaboration revenue we earned from Sanofi is detailed below:

	Three Months Ended September 30,						Nine Months Ended September 30,
Sanofi Collaboration Revenue	2019			2018			2019			2018
Antibody:
Reimbursement of Regeneron research and development expenses	$	60.2		$	76.2		$	216.5		$	201.0
Reimbursement of Regeneron commercialization-related expenses	111.6			103.7			349.3			292.8
Reimbursement for Regeneron's manufacturing of commercial supplies	78.5			40.3			133.3			94.4
Regeneron's share of profits (losses) in connection with commercialization of antibodies	94.2			(38.9		)	105.2			(182.6		)
Other	4.8			(7.2		)	(0.6		)	(12.3		)
Total Antibody	349.3			174.1			803.7			393.3
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	38.0			74.8			120.9			225.7
Reimbursement of Regeneron commercialization-related expenses	3.0			3.2			7.0			6.5
Amounts recognized in connection with up-front payments received	18.5			7.9			73.8			65.2
Other	(4.6		)	(3.7		)	(5.7		)	(7.2		)
Total Immuno-oncology	54.9			82.2			196.0			290.2
	$	404.2		$	256.3		$	999.7		$	683.5

Schedule of accounts receivable and deferred revenue information

The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:

	September 30,		December 31,
	2019		2018
Accounts receivable	$	332.5	$	138.2
Deferred revenue	$	377.0	$	236.1

Significant changes in deferred revenue balances are as follows:

	Nine Months Ended September 30, 2019
Increase due to shipments of commercial supplies to Sanofi	$	294.3
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(159.0	)

The following table summarizes contract balances in connection with the Teva Collaboration Agreement:

	September 30,		December 31,
	2019		2018
Accounts receivable (recorded within Prepaid expenses and other current assets)	$	36.0	$	28.8
Deferred revenue	$	127.8	$	194.5

Significant changes in deferred revenue balances are as follows:

	Nine Months Ended September 30, 2019
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(68.7	)

The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:

	September 30,		December 31,
	2019		2018
Accounts receivable	$	8.2	$	77.9
Deferred revenue	$	602.0	$	289.9

Significant changes in deferred revenue balances are as follows:

	Nine Months Ended September 30, 2019
Increase as a result of payment received from Sanofi in connection with the Amended IO Discovery Agreement	$	415.9
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(73.8	)
Revenue recognized that was added to deferred revenue during the period	$	(37.9	)